retatrutide what is it clinical trial Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Let's talk about a new

New study ties weight-loss drugs Wegovy, Ozempic to serious gastrointestinal conditions Issues like pancreatitis, stomach paralysis higher among patients using GLP-1 inhibitor medications Medicines in the same class as Novo Nordisk's popular weight-loss therapy Wegovy may carry an increased risk of pancreatitis, intestinal blockage and stomach paralysis compared to an older obesity drug, according to a study published on Thursday

What Theyre FDA-Approved For Currently, GLP-1 medications are approved for: Type 2 diabetes Obesity and weight management Reducing cardiovascular risk in people with heart or kidney disease MASH (metabolic-associated steatohepatitis) , formerly called NASH, a type of fatty liver disease Microdosing: What It Means Microdosing usually refers to staying at a very low dosesay, 0.25 mg of semaglutidelong-term, rather than gradually increasing to the therapeutic dose

Hashimotos thyroiditis affects about 1 to 2 percent of people in the United States, according to the National Institutes of Health

Physiological weight loss can help decrease metabolic risk factors and is effective in managing several diseases